Browse

You are looking at 1 - 7 of 7 items

Khaled Aljenaee Department of Endocrinology, St James Hospital, Dublin, Ireland

Search for other papers by Khaled Aljenaee in
Google Scholar
PubMed
Close
,
Osamah Hakami Department of Endocrinology, Royal College of Surgeons in Ireland, Connolly Hospital Blanchardstown, Dublin, Ireland

Search for other papers by Osamah Hakami in
Google Scholar
PubMed
Close
,
Colin Davenport Department of Endocrinology, St Columcille’s Hospital, Dublin, Ireland

Search for other papers by Colin Davenport in
Google Scholar
PubMed
Close
,
Gemma Farrell Department of Clinical Biochemistry, Connolly Hospital, Blanchardstown, Dublin, Ireland

Search for other papers by Gemma Farrell in
Google Scholar
PubMed
Close
,
Tommy Kyaw Tun Department of Endocrinology, Royal College of Surgeons in Ireland, Connolly Hospital Blanchardstown, Dublin, Ireland

Search for other papers by Tommy Kyaw Tun in
Google Scholar
PubMed
Close
,
Agnieszka Pazderska Department of Endocrinology, St James Hospital, Dublin, Ireland

Search for other papers by Agnieszka Pazderska in
Google Scholar
PubMed
Close
,
Niamh Phelan Department of Endocrinology, St James Hospital, Dublin, Ireland

Search for other papers by Niamh Phelan in
Google Scholar
PubMed
Close
,
Marie-Louise Healy Department of Endocrinology, St James Hospital, Dublin, Ireland

Search for other papers by Marie-Louise Healy in
Google Scholar
PubMed
Close
,
Seamus Sreenan Department of Endocrinology, Royal College of Surgeons in Ireland, Connolly Hospital Blanchardstown, Dublin, Ireland

Search for other papers by Seamus Sreenan in
Google Scholar
PubMed
Close
, and
John H McDermott Department of Endocrinology, Royal College of Surgeons in Ireland, Connolly Hospital Blanchardstown, Dublin, Ireland

Search for other papers by John H McDermott in
Google Scholar
PubMed
Close

Summary

Measurement of glycated haemoglobin (HbA1c) has been utilised in assessing long-term control of blood glucose in patients with diabetes, as well as diagnosing diabetes and identifying patients at increased risk of developing diabetes in the future. HbA1c reflects the level of blood glucose to which the erythrocyte has been exposed during its lifespan, and there are a number of clinical situations affecting the erythrocyte life span in which HbA1c values may be spuriously high or low and therefore not reflective of the true level of glucose control. In the present case series, we describe the particulars of three patients with diabetes who had spuriously low HbA1c levels as a result of dapsone usage. Furthermore, we discuss the limitations of HbA1c testing and the mechanisms by which it may be affected by dapsone in particular.

Learning points:

  • Various conditions and medications can result in falsely low HbA1c.

  • Dapsone can lead to falsely low HbA1c by inducing haemolysis and by forming methaemoglobin.

  • Capillary glucose measurement, urine glucose measurements and fructosamine levels should be used as alternatives to HbA1c for monitoring glycaemic control if it was falsely low or high.

Open access
Teresa M Canteros Endocrinology, Metabolism and Nuclear Medicine, Hospital Italinao de Buenos Aires, Buenos Aires, Argentina

Search for other papers by Teresa M Canteros in
Google Scholar
PubMed
Close
,
Valeria De Miguel Endocrinology, Metabolism and Nuclear Medicine, Hospital Italinao de Buenos Aires, Buenos Aires, Argentina

Search for other papers by Valeria De Miguel in
Google Scholar
PubMed
Close
, and
Patricia Fainstein-Day Endocrinology, Metabolism and Nuclear Medicine, Hospital Italinao de Buenos Aires, Buenos Aires, Argentina

Search for other papers by Patricia Fainstein-Day in
Google Scholar
PubMed
Close

Summary

Severe Cushing syndrome (SCS) is considered an emergency that requires immediate treatment to lower serum cortisol levels. Fluconazole may be considered an alternative treatment in Cushing syndrome when ketoconazole is not tolerated or unavailable. We report a 39-year-old woman with a history of partial pancreaticoduodenectomy due to a periampullary neuroendocrine tumor with locoregional extension. Three years after surgery, she developed liver metastases and was started on 120 mg of lanreotide/month, despite which, liver metastases progressed in the following 6 months. The patient showed extreme fatigue, muscle weakness, delirium, moon face, hirsutism and severe proximal weakness. Laboratory tests showed anemia, hyperglycemia and severe hypokalemia. 24-h urinary free cortisol: 2152 nmol/day (reference range (RR): <276), morning serum cortisol 4883.4 nmol/L (RR: 138–690), ACTH 127.3 pmol/L (RR: 2.2–10). She was diagnosed with ectopic ACTH syndrome (EAS). On admission, she presented with acute upper gastrointestinal tract bleeding and hemodynamic instability. Intravenous fluconazole 400 mg/day was started. After 48 h, her mental state improved and morning cortisol decreased by 25%. The dose was titrated to 600 mg/day which resulted in a 55% decrease in cortisol levels in 1 week, but then had to be decreased to 400 mg/day because transaminase levels increased over 3 times the upper normal level. After 18 days of treatment, hemodynamic stability, lower cortisol levels and better overall clinical status enabled successful bilateral adrenalectomy. This case report shows that intravenous fluconazole effectively decreased cortisol levels in SCS due to EAS.

Learning points:

  • Severe Cushing syndrome can be effectively treated with fluconazole to achieve a significant improvement of hypercortisolism prior to bilateral adrenalectomy.

  • Intravenous fluconazole is an alternative treatment when ketoconazole is not tolerated and etomidate is not available.

  • Fluconazole is well tolerated with mild side effects. Hepatotoxicity is usually mild and resolves after drug discontinuation.

Open access
Kewan Hamid Department of Combined Internal Medicine-Pediatrics, Hurley Medical Center, Flint, Michigan, USA

Search for other papers by Kewan Hamid in
Google Scholar
PubMed
Close
,
Neha Dayalani Department of Pediatrics, Hurley Children’s Hospital, Flint, Michigan, USA

Search for other papers by Neha Dayalani in
Google Scholar
PubMed
Close
,
Muhammad Jabbar Department of Pediatrics, Hurley Children’s Hospital, Flint, Michigan, USA
Division of Pediatric Endocrinology, Hurley Children’s Hospital, Flint, Michigan, USA

Search for other papers by Muhammad Jabbar in
Google Scholar
PubMed
Close
, and
Elna Saah Department of Pediatrics, Hurley Children’s Hospital, Flint, Michigan, USA
Division of Pediatric Hematology and Oncology, Hurley Children’s Hospital, Flint, Michigan, USA

Search for other papers by Elna Saah in
Google Scholar
PubMed
Close

Summary

A 6-year-old female presented with chronic intermittent abdominal pain for 1 year. She underwent extensive investigation, imaging and invasive procedures with multiple emergency room visits. It caused a significant distress to the patient and the family with multiple missing days at school in addition to financial burden and emotional stress the child endured. When clinical picture was combined with laboratory finding of macrocytic anemia, a diagnosis of hypothyroidism was made. Although chronic abdominal pain in pediatric population is usually due to functional causes such as irritable bowel syndrome, abdominal migraine and functional abdominal pain. Hypothyroidism can have unusual presentation including abdominal pain. The literature on abdominal pain as the main presentation of thyroid disorder is limited. Pediatricians should exclude hypothyroidism in a patient who presents with chronic abdominal pain. Contrast to its treatment, clinical presentation of hypothyroidism can be diverse and challenging, leading to a delay in diagnosis and causing significant morbidity.

Learning points:

  • Hypothyroidism can have a wide range of clinical presentations that are often nonspecific, which can cause difficulty in diagnosis.

  • In pediatric patients presenting with chronic abdominal pain as only symptom, hypothyroidism should be considered by the pediatricians and ruled out.

  • In pediatric population, treatment of hypothyroidism varies depending on patients’ weight and age.

  • Delay in diagnosis of hypothyroidism can cause significant morbidity and distress in pediatrics population.

Open access
Chad Bisambar NHS Ayrshire and Arran, Ayr, UK

Search for other papers by Chad Bisambar in
Google Scholar
PubMed
Close
,
Andrew Collier NHS Ayrshire and Arran, Ayr, UK

Search for other papers by Andrew Collier in
Google Scholar
PubMed
Close
,
Fraser Duthie NHS Greater Glasgow and Clyde, Glasgow, UK

Search for other papers by Fraser Duthie in
Google Scholar
PubMed
Close
, and
Carron Meney NHS Ayrshire and Arran, Ayr, UK

Search for other papers by Carron Meney in
Google Scholar
PubMed
Close

Summary

A 40-year-old Caucasian female presented with hyperglycaemia, polyuria, polydipsia and weight loss of 6 kg over a 1-month period. There was no personal or family history of malignancy or diabetes mellitus. On examination, she was jaundiced with pale mucous membranes and capillary glucose was 23.1 mmol/L. Initial investigations showed iron deficiency anaemia and obstructive pattern of liver function tests. HbA1c was diagnostic of diabetes mellitus at 79 mmol/mol. Malignancy was suspected and CT chest, abdomen and pelvis showed significant dilatation of intra- and extra-hepatic biliary tree including pancreatic duct, with periampullary 30 mm mass lesion projecting into lumen of duodenum. Enlarged nodes were seen around the superior mesenteric artery. This was confirmed on MRI liver. Fasting gut hormones were normal except for a mildly elevated somatostatin level. Chromogranin A was elevated at 78 pmol/L with normal chromogranin B. Duodenoscopy and biopsy showed possible tubovillous adenoma with low-grade dysplasia, but subsequent endoscopic ultrasound and biopsy revealed a grade 1, well differentiated neuroendocrine tumour. The patient was started on insulin, transfused to Hb >8 g/dL and Whipple’s pancreatico-duodenectomy was undertaken. This showed a well-differentiated neuroendocrine carcinoma arising in duodenum (Grade G1 with Ki67: 0.5%), with areas of chronic pancreatitis and preservation of pancreatic islet cells. There was complete resolution of diabetes post Whipple’s procedure and patient was able to come of insulin treatment. Her last HBA1C was 31 mmol/mol, 4 months post tumour resection.

Learning points:

  • Diabetes mellitus and malignancy can be related.

  • A high index of suspicion is needed when diabetes mellitus presents atypically.

  • Non-functional neuroendocrine tumours can present with diabetes mellitus.

Open access
Usman Javaid Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK

Search for other papers by Usman Javaid in
Google Scholar
PubMed
Close
,
Vikram Lal Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK

Search for other papers by Vikram Lal in
Google Scholar
PubMed
Close
,
Catherine Napier Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK

Search for other papers by Catherine Napier in
Google Scholar
PubMed
Close
,
Alison Burbridge Department of Neurorehabilitation, Northumbria, Tyne & Wear NHS Trust, Newcastle-upon-Tyne, UK

Search for other papers by Alison Burbridge in
Google Scholar
PubMed
Close
, and
Richard Quinton Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK
Institute of Genetic Medicine, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK

Search for other papers by Richard Quinton in
Google Scholar
PubMed
Close

Hypogonadal men may experience intense vasomotor symptoms, and vasomotor sweating can occasionally be associated with profound fluid losses. We describe a 37-year-old male, who exhibited persistent hypovolaemic hypernatraemia that was challenging to treat despite a continuous high fluid input (>4–5 L/day). He was noted to have drenching sweats and normochromic anaemia. He had recent traumatic head injury, which resulted in neurocognitive dysfunction, so pituitary function tests were done which showed primary hypogonadism. After exclusion of all other possible causes of excess sweating, hypernatraemia and anaemia, a trial of testosterone therapy was instituted. Sweating dramatically ceased within hours of his first testosterone injection, hydration status normalised within days and anaemia and neurocognitive function progressively improved with continued testosterone replacement. This case demonstrates how, in a susceptible individual, hypovolaemic hypernatraemia can arise from insensible cutaneous fluid loss through eccrine sweating, mediated by vasomotor symptoms of untreated hypogonadism. Although this scenario has not been described in the literature, we felt it needed to be shared with the wider medical community because of how the diagnosis and treatment utterly transformed this patient’s functional status and outcome.

Learning points:

  • Hypogonadal men may experience intense vasomotor symptoms and vasomotor sweating can occasionally be associated with profound fluid losses.

  • Whether or not there is also hyperosmolar hypernatraemia, clinicians should always consider the possibility of underlying hypogonadism in men with normocytic anaemia and excessive sweating.

  • Androgen (testosterone) replacement in hypogonadal men can have a dramatic effect on vasomotor sweating and hot flushes.

Open access
M Horsey Georgetown University School of Medicine, Washington, District of Columbia, USA

Search for other papers by M Horsey in
Google Scholar
PubMed
Close
,
P Hogan Walter Reed National Military Medical Center, Bethesda, Maryland, USA

Search for other papers by P Hogan in
Google Scholar
PubMed
Close
, and
T Oliver Walter Reed National Military Medical Center, Bethesda, Maryland, USA

Search for other papers by T Oliver in
Google Scholar
PubMed
Close

Summary

A 71-year-old woman with severe right lower leg pain, edema and erythema was presented to the Emergency Department and was found to have an extensive deep vein thrombosis (DVT) confirmed by ultrasound. She underwent an extensive evaluation due to her prior history of malignancy and new hypercoagulable state, but no evidence of recurrent disease was detected. Further investigation revealed pernicious anemia (PA), confirmed by the presence of a macrocytic anemia (MCV=115.8fL/red cell, Hgb=9.0g/dL), decreased serum B12 levels (56pg/mL), with resultant increased methylmalonic acid (5303nmol/L) and hyperhomocysteinemia (131μmol/L), the presumed etiology of the DVT. The patient also suffered from autoimmune thyroid disease (AITD), and both antithyroglobulin and anti-intrinsic factor antibodies were detected. She responded briskly to anticoagulation with heparin and coumadin and treatment of PA with intramuscular vitamin B12 injections. Our case suggests that a DVT secondary to hyperhomocystenemia may represent the first sign of polyglandular autoimmune syndrome III-B (PAS III-B), defined as the coexistent autoimmune conditions AITD and PA. It is important to recognize this clinical entity, as patients may not only require acute treatment with vitamin B12 supplementation and prolonged anticoagulation, as in this patient, but may also harbor other autoimmune diseases.

Learning points

  • A DVT can be the first physical manifestation of a polyglandular autoimmune syndrome.

  • Hyperhomocysteinemia secondary to pernicious anemia should be considered as an etiology of an unprovoked DVT in a euthyroid patient with autoimmune thyroid disease.

  • Patients with DVT secondary to hyperhomocysteinemia should undergo screening for the presence of co-existent autoimmune diseases in addition to treatment with B12 supplementation and anticoagulation to prevent recurrent thromboembolism.

Open access
Mohd Shazli Draman Department of Diabetes and Endocrinology, St James's Hospital, James's Street, Dublin 8, Ireland

Search for other papers by Mohd Shazli Draman in
Google Scholar
PubMed
Close
,
Aoife Brennan Department of Diabetes and Endocrinology, St James's Hospital, James's Street, Dublin 8, Ireland

Search for other papers by Aoife Brennan in
Google Scholar
PubMed
Close
,
Michael Cullen Department of Diabetes and Endocrinology, St James's Hospital, James's Street, Dublin 8, Ireland

Search for other papers by Michael Cullen in
Google Scholar
PubMed
Close
, and
John Nolan Department of Diabetes and Endocrinology, St James's Hospital, James's Street, Dublin 8, Ireland

Search for other papers by John Nolan in
Google Scholar
PubMed
Close

Summary

Bilateral lower limb paraesthesia is a common diabetic neuropathy presentation in any busy diabetic clinics. We present a case of a 28-year-old man with a long history of type 1 diabetes mellitus presented with bilateral paraesthesia of both feet and unsteady gait. The patient was able to feel a 10 g monofilament. The presence of brisk reflexes and upgoing plantars in this patient were pointers that further evaluation was warranted. Further investigations revealed diagnosis of subacute combined degeneration of spinal cord. The patient had rapid symptomatic improvement with i.m. vitamin B12 injection. The high volume of patients attending the outpatients with diabetes and paraesthesia can blind us to other possible diagnoses. This article emphasizes that peripheral neuropathy in a diabetic may be due to aetiologies other than diabetes.

Learning points

  • Pernicious anaemia is known to be more common in patients with type 1 diabetes.

  • Cobalamin deficiency is reversible if detected early enough and treated by B12 replacement.

  • By contrast, diabetic neuropathy is generally a progressive complication of diabetes.

  • Peripheral neuropathy in a diabetic may be due to aetiologies other than diabetes.

Open access